Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice

Sci Rep. 2016 Jun 21:6:28200. doi: 10.1038/srep28200.

Abstract

Galanin-like peptide (GALP) has an anti-obesity effect in rats and mice. It has been reported that the uptake of GALP by the brain is higher after intranasal administration than with intravenous injection. This study therefore aimed to clarify the effect of intranasal administration of GALP on the feeding behavior of lean and obese mice. Autoradiography revealed the presence of (125)I-GALP in the olfactory bulb and the brain microcirculation. The body weights of ob/ob mice gradually increased during vehicle treatment, but remained unchanged in response to repeated intranasal administration of GALP, with both ob/ob and diet-induced obese mice displaying significantly decreased food intake, water intake and locomotor activity when treated with GALP. These results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Anti-Obesity Agents / therapeutic use*
  • Autoradiography
  • Body Weight
  • Brain / pathology*
  • Energy Metabolism
  • Galanin-Like Peptide / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Obesity / drug therapy*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Anti-Obesity Agents
  • Galanin-Like Peptide